Safety of sertindole versus risperidone in schizophrenia: Principal results of the sertindole cohort prospective study (SCoP)

Acta Psychiatrica Scandinavica

Volumn 122, Issue 5, 2010, Pages 345-355

  Thomas, S H L ^a   Drici, M D ^b   Hall, G C ^c   Crocq, M A ^d   Everitt, B ^e   Lader, M H ^e   Jeunne, C Le ^f   Naber, D ^g   Priori, S ^h   Sturkenboom, M ⁱ   Thibaut, F ^j   Peuskens, J ^k   Mittoux, A ^l   Tanghoj P ^l   Toumi, M ^m   Moore, N D ⁿ   Mann, R D ^o  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b PASTEUR HOSPITAL   (France)

^c Grimsdyke House   (United Kingdom)

^d CENTRE HOSPITALIER DE MULHOUSE   (France)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f HÔTEL DIEU   (France)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j HÔPITAL CHARLES NICOLLE   (France)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l H LUNDBECK A S   (Denmark)

^m UNIVERSITÉ LYON 1   (France)

ⁿ HÔPITAL PELLEGRIN   (France)

^o UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

all cause mortality; risperidone; safety; schizophrenia; sertindole

Indexed keywords

RISPERIDONE; SERTINDOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ARRHYTHMIAS, CARDIAC; FEMALE; HEART DISEASES; HOSPITALIZATION; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SUICIDE, ATTEMPTED; YOUNG ADULT;

EID: 77957350060     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01563.x     Document Type: Article

References (34)

1. Titier K, Girodet P-O, Verdoux H et al. Atypical antipsychotics: from potassium channel to torsade de pointes and sudden death. Drug Saf 2005 28 : 35 51.
2. Drici M-D, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Saf 2007 16 : 882 890.
3. Lindstrom E, Farde L, Eberhard J, Haverkamp W. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 2005 8 : 615 629.
4. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacol 1996 124 : 168 175.
5. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997 12 (Suppl 1 S29 S35.
6. Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psych 1997 154 : 782 791.
7. Daniel DG, Wozniak P, Mack RJ, McCarthy BG. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998 34 : 61 69.
8. Hale A, Azorin J-M, Kasper S et al. Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of a Phase III trial. Int J Psych Clin Pract 2000 4 : 47 54.
9. Hale A, Azorin J-M, Kasper S et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a Phase III trial. Int J Psych Clin Pract 2000 4 : 55 62. (Pubitemid 30198337)
10. Azorin J-M, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 2006 21 : 49 56.
11. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharm Expt Ther 1998 286 : 788 793.
12. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. Comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002 16 : 37 41.
13. Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharm 1998 18 : 477 481.
14. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsades de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 2002 300 : 64 71.
15. Nielsen J, Graff C, Hardahi T et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharm 2009 19 : 702 707.
16. Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003 12 : 271 281.
17. Wilton LV, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001 15 : 120 126.
18. Peuskens J, Moore N, Azorin J-M, Toumi M, Cochran J. The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol Drug Saf 2007 16 : 804 811.
19. Peuskens J, Tanghøj P, Mittoux A. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. Pharmacoepidemiol Drug Saf 2008 17 : 425 433.
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979 35 : 549 556.
21. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997 171 : 502 508.
22. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr Bull 1989 15 : 81 89.
23. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000 177 : 212 217.
24. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiatry 2001 179 : 498 502.
25. Heilä H, Haukka J, Suvisaari J, Lönnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 2005 35 : 725 732.
26. Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 2006 15 : 873 879.
27. Limosin F, Loze JY, Philippe A, Casadebaig F, Rouillon F. Ten-year prospective follow-up study of the mortality by suicide in schizophrenic patients. Schizophr Res 2007 94 : 23 28.
28. Thirtalli J, Venkatesh BK, Kishorekumar KV et al. Prospective comparison of course of disability in antipsychotic-treated and untreated schizophrenia patients. Acta Psych Scand 2009 119 : 209 217.
29. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc Interval, torsade de pointes, and sudden death. Am J Psychiatry 2001 158 : 1774 1782.
30. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005 19 (Suppl 1 1 93.
31. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or metabolic risk? Acta Psychiatr Scand 2009 119 : 171 179.
32. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. New Engl J Med 2009 360 : 225 235.
33. Strom BL, Faich GA, Reynolds RF et al. The Ziprasidone Observational study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. J Clin Psych 2008 69 : 114 121.
34. Eng SM, Strom BL, Faich G et al. Comparative mortality associated with ziprasidone versus olanzapine in real world use: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Schizophr Res 2008 98 (Suppl 1 160 161.